Intravenous immunoglobulin and suppression of the production of matrix metalloproteinase‐9 | Zendy

Matsuo Hidenori | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Intravenous immunoglobulin and suppression of the production of matrix metalloproteinase‐9

Author(s) -

Matsuo Hidenori

Publication year - 2015

Publication title -

clinical and experimental neuroimmunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.297

H-Index - 15

ISSN - 1759-1961

DOI - 10.1111/cen3.12223

Subject(s) - multiple sclerosis , matrix metalloproteinase , matrix metalloproteinase 9 , antibody , metalloproteinase , tissue inhibitor of metalloproteinase , in vitro , matrix (chemical analysis) , medicine , immunology , immunoglobulin g , matrix metalloproteinase 3 , chemistry , biochemistry , chromatography

Matrix metalloproteinase‐9 is a biomarker and therapeutic target in multiple sclerosis. Okada and Adachi reported the matrix metalloproteinase‐9/tissue inhibitor of metalloproteinase‐1 imbalance was a predisposition in patients with multiple sclerosis, and human immunoglobulin G restored it in vitro , supporting the potential of intravenous immunoglobulin therapy in multiple sclerosis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research